siRNA ErbB receptor family inhibitors (Celon Pharma)

N/A

Report date: 2025/03/20 20:00:06

NME

Base Information

Drug NamesiRNA ErbB receptor family inhibitors (Celon Pharma)

Drug Alias NamesiRNA epidermal growth factor family member inhibitors (Celon Pharma)

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsReceptor protein-tyrosine kinase erbB-4 inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists +[4]

TargetsReceptor protein-tyrosine kinase erbB-4Epidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB-3 +[4]

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryPoland

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCelon Pharma SP

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCelon Pharma SP

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A